1. Home
  2. TGLS vs ZYME Comparison

TGLS vs ZYME Comparison

Compare TGLS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

HOLD

Current Price

$53.33

Market Cap

2.5B

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$23.15

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGLS
ZYME
Founded
1984
2003
Country
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TGLS
ZYME
Price
$53.33
$23.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$80.00
$32.75
AVG Volume (30 Days)
275.8K
590.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.04
$63.10
Revenue Next Year
$10.69
$93.26
P/E Ratio
$13.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.26
$9.03
52 Week High
$90.34
$28.49

Technical Indicators

Market Signals
Indicator
TGLS
ZYME
Relative Strength Index (RSI) 58.39 48.12
Support Level $47.28 $22.07
Resistance Level $54.85 $23.52
Average True Range (ATR) 1.79 0.88
MACD 0.37 0.09
Stochastic Oscillator 79.00 60.44

Price Performance

Historical Comparison
TGLS
ZYME

About TGLS Tecnoglass Inc.

Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: